On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately. Topics to be covered include:
New Pre-NOC Review Procedure & Submission Criteria
New Submission Guidelines
New Submission Requirements
Potential Changes to List ... Read More
09
Jun2017
06
Jun2017
On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately.
Pre-NOC Review
Moving forward, INESSS will evaluate certain drug products (see the criteria here on the INESSS website) before a Notice of Compliance ... Read More
30
May2017
Consultation on Potential Changes to the Patented Medicines Regulations
On May 16, 2017, the Honourable Jane Philpott, Minister of Health, outlined a comprehensive plan for improving the pharmaceutical system in Canada. Included in the plan was the launch of a consultation process on potential changes to the Patented Medicines Regulations (Regulations) ... Read More
25
May2017
On Tuesday, May 16, 2017, Federal Health Minister Hon. Jane Philpott opened consultations on a suite of amendments to the Patented Medicines Regulations that will have significant effects on how patented drug prices are regulated in Canada. The implementation of these proposed amendments could represent the most important changes in ... Read More
16
May2017
Health Minister Hon. Jane Philpott Announces Consultations on proposed changes to the Patented Medicines Regulations
Speaking today at the Economic Club of Canada in Ottawa, Federal Health Minister Jane Philpott announced the opening of a consultation period concerning proposed changes to the Patented Medicines Regulations that would have significant effects ... Read More
16
May2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017:
38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017:
Cosentyx (secukinumab): Use to treat psoriatic arthritis
Cosentyx (secukinumab): Used to treat ... Read More
03
May2017
PDCI Market Access is delighted to announce the addition of John-Paul Dowson to the PDCI team as an external Advisor and Strategic Partner. John-Paul is Managing Director of Roubaix Strategies Inc., an advisory firm dedicated to helping organizations evaluate, develop and implement highly effective private and public market access strategies, ... Read More
02
May2017
Join PDCI at 3rd Annual Canadian Institute Pharma Symposium
PDCI Market Access is delighted to participate in the 3rd Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders in pharmaceutical market access & policy to analyze the key issues facing the industry in today’s complex environment. Participants will ... Read More
19
Apr2017
The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early ... Read More
19
Apr2017
The drug products being evaluated as part of the October 2017 update to the List of Medications now been made public by INESSS. Health professionals, citizens, patients, and their associations and groups may submit comments on any of the products under consideration before May 12, 2017. As part of this ... Read More